Aimed Alliance has signed on to the Coalition for Accessible Treatments’ letter commenting on the proposed rule, Notice of Benefit and Payment Parameters for 2017 (80 FR, Dec. 2, 2015), urging the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) to consider the historical context of specialty tiers and cost-sharing rates across markets, not just in the Health Care Marketplace Exchanges, in its methodology for setting co-insurance rates in the standardized plans’ specialty tiers. The letter emphasizes that the proposed rates are not line with other markets and would place an undue financial hardship on many patients who must have access to these drugs in order to control their disease. Plan disclosure should include at a minimum, a drug formulary and tier placement for each drug; copayment, co-insurance, and deductible levels; and up-to-date provider directories. Therefore, the HHS and CMS must continue to make transparency a priority and work to refine patient tools in the coming months and years.
You can read the letter in full here.
Last Updated on May 7, 2020 by Aimed Alliance
